NASDAQ:OTIC
Delisted
Otonomy Stock News
$0.0085
+0 (+0%)
At Close: Jul 11, 2023
Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
07:30am, Thursday, 04'th Feb 2021
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will
Otonomy to Participate in the H.C. Wainwright BioConnect 2021 Virtual Conference
07:30am, Tuesday, 05'th Jan 2021
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that ma
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss
07:00am, Thursday, 17'th Dec 2020
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positiv
Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs
07:30am, Monday, 30'th Nov 2020
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided updates
Otonomy to Participate in Two Upcoming Investor Conferences
07:30am, Monday, 16'th Nov 2020
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that ma
Otonomy, Inc. (OTIC) CEO David Weber on Q3 2020 Results - Earnings Call Transcript
07:29pm, Wednesday, 04'th Nov 2020
Otonomy, Inc. (OTIC) CEO David Weber on Q3 2020 Results - Earnings Call Transcript
Otonomy (OTIC) Reports Q3 Loss, Misses Revenue Estimates
06:55pm, Wednesday, 04'th Nov 2020
Otonomy (OTIC) delivered earnings and revenue surprises of 12.00% and -54.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Otonomy, Inc. (OTIC) CEO David Weber On Q3 2020 Results - Quick Version Earnings Call Transcript
05:41pm, Wednesday, 04'th Nov 2020
Otonomy, Inc. (OTIC) CEO David Weber On Q3 2020 Results - Quick Version Earnings Call Transcript
Otonomy: Q3 Earnings Insights
05:03pm, Wednesday, 04'th Nov 2020
Shares of Otonomy (NASDAQ:OTIC) were flat after the company reported Q3 results. Quarterly Results Earnings per share were up 33.33% over the past year to ($0.22), which beat the estimate of ($0.24).
Otonomy to Report Third Quarter 2020 Financial Results and Provide Corporate Update
07:30am, Wednesday, 28'th Oct 2020
SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
12:00am, Wednesday, 19'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
Billionaire Steven Cohen Pulls the Trigger on These 3 Penny Stocks
07:30pm, Monday, 17'th Aug 2020
There are two sides to every coin. For penny stocks, or tickers that trade for less than $5 per share, this rings especially true. As some of the most divisive names on the Street, they are either met
Otonomy (OTIC) Reports Q2 Loss, Lags Revenue Estimates
11:25pm, Tuesday, 04'th Aug 2020
Otonomy (OTIC) delivered earnings and revenue surprises of -2.78% and -92.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update
08:22pm, Tuesday, 04'th Aug 2020
* Positive top-line results reported for Phase 1/2 trial of OTO-313 in tinnitus patients * Public offering completed for total gross proceeds of $69.1 million * Results from Phase 3 trial of OTIVI
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
ABIOMED, Inc. (NASDAQ: ABMD)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Annexon Inc (NASDAQ: ANNX)
Atossa...
